Suppression of the Transformed Phenotype and Induction of Differentiation-Like Characteristics in Cultured Ovarian Tumor Cells by Chronic Treatment with Progesterone

Molecular Carcinogenesis

Volumn 38, Issue 4, 2003, Pages 160-169

  Blumenthal, Martina ^a   Kardosh, Adel ^a   Dubeau, Louis ^b   Borok, Zea ^b   Schönthal, Axel H ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cell cycle; Differentiation; Ovarian carcinoma; Progesterone

Indexed keywords

CA 125 ANTIGEN; CYCLIN DEPENDENT KINASE; HEAT SHOCK PROTEIN 72; PROGESTERONE; TUMOR MARKER;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RISK; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTACT INHIBITION; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION;

BLOTTING, WESTERN; CA-125 ANTIGEN; CELL ADHESION; CELL DIFFERENTIATION; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASES; CYCLINS; EPITHELIUM; FEMALE; HEAT-SHOCK PROTEINS; HSP72 HEAT-SHOCK PROTEINS; HUMANS; OVARIAN NEOPLASMS; PROGESTERONE; TUMOR CELLS, CULTURED;

EID: 0346243739     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.10155     Document Type: Article

References (53)

1. American Cancer Society. Cancer Facts and Figures. 2002.
2. Cramer DW, Hutchison GB, Welch WR, Scully RE, Ryan KJ. Determinants of ovarian cancer risk. 1. Reproductive experiences and family history. J Natl Cancer Inst 1983;71:711-716.
3. Cramer DW, Hutchison GB, Welch WR, Scully RE, Knapp RC. Factors affecting the association of oral contraceptives and ovarian cancer. N Engl J Med 1982;307:1047-1051.
4. Edmondson RJ, Monaghan JM. The epidemiology of ovarian cancer. Int J Gynecol Cancer 2001;11:423-429.
5. Makar AP. Hormone therapy in epithelial ovarian cancer. Endocr Relat Cancer 2000;7:85-93.
6. Riman T, Persson I, Nilsson S. Hormonal aspects of epithelial ovarian cancer: Review of epidemiological evidence. Clin Endocrinol 1998;49:695-707.
7. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90:1774-1786.
8. Casagrande JT, Louie EW, Pike MC, Roy S, Ross RK, Henderson BE. "Incessant ovulation" and ovarian cancer. Lancet 1979;2:170-173.
9. Fathalla MF. Incessant ovulation - A factor in ovarian neoplasia? Lancet 1971;2:163.
10. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983;71:717-721.
11. Adami HO, Hsieh CC, Lambe M, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet 1994;344:1250-1254.
12. Risch HA, Weiss NS, Lyon JL, Daling JR, Liff JM. Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol 1983;117:128-139.
13. Yu S, Lee M, Shin S, Park J. Apoptosis induced by progesterone in human ovarian cancer cell line SNU-840. J Cell Biochem 2001;82:445-451.
14. Keith Bechtel M, Bonavida B. Inhibitory effects of 17beta-estradiol and progesterone on ovarian carcinoma cell proliferation: A potential role for inducible nitric oxide synthase. Gynecol Oncol 2001;82:127-138.
15. Bu SZ, Yin DL, Ren XH, et al. Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer 1997;79:1944-1950.
16. Ivarsson K, Sundfeldt K, Brannstrom M, Janson PO. Production of steroids by human ovarian surface epithelial cells in culture: Possible role of progesterone as growth inhibitor. Gynecol Oncol 2001;82:116-121.
17. Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 2001;61:6768-6776.
18. Zhou H, Luo M, Schönthal AH, et al. Regulation of ovarian epithelial tumor growth by menstrual cycle hormones. Cancer Biol Therapy 2002;1:300-306.
19. Buick RN, Pullano R, Trent JM. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 1985; 45:3668-3676.
20. Harlow E, Lane D. Antibodies: A laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1988.
21. Wu R-C, Schönthal AH. Activation of p53-p21waf1 pathway in response to disruption of cell-matrix interactions. J Biol Chem 1997;272:29091-29098.
22. Thomas CM, Massuger LF, Segers MF, Schijf CP, Doesburg WH, Wobbes T. Analytical and clinical performance of improved Abbott IMx CA 125 assay: Comparison with Abbott CA 125 RIA. Clin Chem 1995;41:211-216.
23. - fluxes to net ion transport by alveolar epithelium. Respir Physiol 1991;85:245-256.
24. Tsao SW, Mok SC, Fey EG, et al. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp Cell Res 1995;218:499-507.
25. Nakamura M, Katabuchi H, Ohba T, Fukumatsu Y, Okamura H. Isolation, growth, and characteristics of human ovarian surface epithelium. Virchows Arch 1994;424:59-67.
26. Anderson JM, Van Itallie CM. Tight junctions: Closing in on the seal. Curr Biol 1999;9:R922-R924.
27. Diamond JM. The epithelial junction: Bridge, gate, and fence. Physiologist 1977;20:10-18.
28. Sutherland RL, Prall OW, Watts CK, Musgrove EA. Estrogen and progestin regulation of cell cycle progression. J Mammary Gland Biol Neoplasia 1998;3:63-72.
29. Swarbrick A, Lee CS, Sutherland RL, Musgrove EA. Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells. Mol Cell Biol 2000; 20:2581-2591.
30. Musgrove EA, Swarbrick A, Lee CS, Cornish AL, Sutherland RL. Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol Cell Biol 1998;18:1812-1825.
31. Owen GI, Richer JK, Tung L, Takimoto G, Horwitz KB. Progesterone regulates transcription of the p21(WAF1) cyclin-dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem 1998;273:10696-10701.
32. Xiong Y, Hannon GJ, Zhang GJ, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366:701-704.
33. 2 checkpoint through cyclin B1. Proc Natl Acad Sci USA 1999;96:2147-2152.
34. 2 arrest in response to overexpression of p53. Mol Biol Cell 1999;10:3607-3622.
35. Volloch VZ, Sherman MY. Oncogenic potential of Hsp72. Oncogene 1999;18:3648-3651.
36. Athanassiadou P, Petrakakou E, Sakelariou V, et al. Expression of p53, bcl-2, and heat shock protein (hsp72) in malignant and benign ovarian tumours. Eur J Cancer Prev 1998;7:225-231.
37. Koshiyama M, Konishi I, Mandai M, et al. Immunohistochemical analysis of p53 protein and 72 kDa heat shock protein (HSP72) expression in ovarian carcinomas. Correlation with clinicopathology and sex steroid receptor status. Virchows Arch 1995;425:603-609.
38. Davis HM, Zurawski VR, Jr., Bast RC, Jr., Klug TL. Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Res 1986;46:6143-6148.
39. Kabawat SE, Bast RC, Welch WR, Knapp RC, Colvin RB. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol 1983;79:98-104.
40. Bast RC, Jr., Klug TL, St. John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-887.
41. von Schlippe M, Rustin GJ. Circulating tumour markers in ovarian tumours. Forum (Genova) 2000;10:383-392.
42. McDonnel AC, Van Kirk EA, Isaak DD, Murdoch WJ. Inhibitory effects of progesterone on plasma membrane fluidity and tumorigenic potential of ovarian epithelial cancer cells. Exp Biol Med 2003;228:308-314.
43. McDonnel AC, Murdoch WJ. High-dose progesterone inhibition of urokinase secretion and invasive activity by SKOV-3 ovarian carcinoma cells: Evidence for a receptor-independent nongenomic effect on the plasma membrane. J Steroid Biochem Mol Biol 2001;78:185-191.
44. Schneeberger EE, Lynch RD. Structure, function, and regulation of cellular tight junctions. Am J Physiol 1992;262:L647-L661.
45. Gumbiner BM. Breaking through the tight junction barrier. J Cell Biol 1993;123:1631-1633.
46. Buse P, Woo PL, Alexander DB, et al. Transforming growth factor-alpha abrogates glucocorticoid-stimulated tight junction formation and growth suppression in rat mammary epithelial tumor cells. J Biol Chem 1995;270:6505-6514.
47. Garcia de Herreros A, Fabre M, Batlle E, Balague C, Real FX. The tumor promoter 12-O-tetradecanoylphorbol-13-acetate blocks differentiation of HT-29 human colon cancer cells. J Cell Sci 1993;105:1165-1172.
48. Brann DW, Hendry LB, Mahesh VB. Emerging diversities in the mechanism of action of steroid hormones. J Steroid Biochem Mol Biol 1995;52:113-133.
49. Golden GA, Mason PE, Rubin RT, Mason RP. Biophysical membrane interactions of steroid hormones: A potential complementary mechanism of steroid action. Clin Neuropharmacol 1998;21:181-189.
50. Brenner PF, Mishell DR, Jr., Stanczyk FZ, Goebelsmann U. Serum levels of D-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing D-L-norgestrel. Am J Obstet Gynecol 1977;129:133-140.
51. Clement PB. Histology of the ovary. Am J Surg Pathol 1987; 11:277-303.
52. Channing CP, Schaerf FW, Anderson LD, Tsafriri A. Ovarian follicular and luteal physiology. Int Rev Physiol 1980;22:117-201.
53. Lucisano A, Dell'Acqua S, Montemurro A, et al. Peripheral and ovarian vein plasma levels of 20alpha-dihydroprogesterone in women with normal menstrual cycles. J Steroid Biochem 1978;9:643-648.